Moderna Reiterates Its 2024 Expected Net Product Sales Of $3.0B-$3.5B From Its Respiratory Franchise
Moderna Reiterates Its 2024 Expected Net Product Sales Of $3.0B-$3.5B From Its Respiratory Franchise
modern复申报其2024年预期的净产品销售额为30亿美元。从其呼吸产品系列中为35亿美元。
2024 Financial Framework
2024 Financial Framework
- Net Sales: The Company reiterates its 2024 expected net product sales of $3.0 to $3.5 billion from its respiratory franchise.
- Cost of Sales: Cost of sales is now expected to be in the range of 40-45% of product sales for the year (previously 40-50%).
- Research and Development Expenses: Full-year 2024 research and development expenses are now anticipated to be in the range of $4.6 to $4.7 billion (previously $4.8 billion).
- Selling, General and Administrative Expenses: Selling, general and administrative expenses for 2024 are projected to be approximately $1.2 billion.
- Income Taxes: The Company continues to expect its full-year tax expense to be negligible.
- Capital Expenditures: Capital expenditures for 2024 are now expected to be approximately $1.2 billion (previously ~$0.9 billion). The updated estimate includes the purchase of the Norwood, MA, campus for ~$0.4 billion.
- Cash and Investments: Year-end cash and investments for 2024 are projected to be approximately $9 billion.
- 净销售额：公司重申其2024年预期的呼吸产品净销售额为30亿至35亿美元。
- 销售成本：销售成本预计在年度产品销售额的40-45%区间内（先前为40-50%）。
- 研发支出：2024年全年研发支出预计在46亿至47亿美元的区间内（先前为48亿美元）。
- 销售、一般及管理费用：2024年销售、一般及管理费用预计约为12亿美元。
- 所得税：公司仍预期全年税费将微不足道。
- 资本支出：2024年资本支出预计约为12亿美元（先前约为9亿美元）。更新的估算包括购买位于马萨诸塞州诺伍德市的校园，约4亿美元。
- 现金及投资：2024年年底的现金和投资预计约为90亿美元。
资讯热榜
更新时间